Breast cancer patient featured in The Cancer Letter receives testing for COVID-19, awaits results

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Last week, The Cancer Letter spoke with Janice Cowden, a patient with metastatic breast cancer and symptoms of COVID-19—who was denied testing despite being especially vulnerable to the disease (The Cancer Letter, March 20).

Cowden has since received two tests for COVID-19—a nasopharyngeal swab at a curbside clinic, and a throat pharyngeal swab at the office of her primary care physician. She has yet to receive the results of either test.

Prior to developing symptoms, Cowden had attended a fundraiser with about 300 people—including dozens of women with metastatic breast cancer.

Table of Contents

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login